Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Biliary Tract Cancer: early-phase trial registry
24 of 37 indexed Biliary Tract Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #406 of 28,707 conditions by registered trial count.
37 US clinical trials · 24 currently recruiting · #406 of 28,707 conditions by registered trial count
Biliary Tract Cancer: 37 US clinical trials tracked, 24 recruiting.
Biliary Tract Cancer is the subject of 37 registered US clinical trials on ClinicalTrials.gov, 24 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 9 of these trials.
Enrollment posture brief
Registry condition biliary-tract-cancer
OPEN 24 | RECR 65% | LATE 5 | EARLY 28 | RANK #406 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Focal Segmental Glomerulosclerosis (65% recruiting · 20 trials)
Biliary Tract Cancer lists 24 open slots (65% of 37 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Biliary Tract Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Biliary Tract Cancer is recruiting above its size-band peers.
24 of 37 indexed trials (64.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Biliary Tract Cancer research.
AstraZeneca accounts for 9 of 37 trials (24.3%). 26 distinct sponsors appear on at least one study for this condition label.
-
Typical Biliary Tract Cancer enrolment sits around 117 participants.
Median target enrolment is 117 among the 37 trials that report a genuine target (sentinel values excluded). 16 of those (43.2%) plan for fewer than 100 participants.
-
Biliary Tract Cancer research is mostly interventional.
35 interventional and 2 observational studies make up this index (94.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
37 total, page 1 of 1
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
AstraZeneca
NCT07221253
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
AstraZeneca
NCT06467357
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
NCT05775159
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
NCT06282575
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NCT06219941
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme
NCT06428409
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co.
NCT05784688
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune
NCT07021066
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
NCT06921928
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
NCT03482102
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT06789848
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune
NCT05733598
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT03801083
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06731998
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT07146646
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
NCT06546969
Extracellular RNA Markers of Liver Disease and Cancer
Mayo Clinic
NCT02908048
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
NCT06109779
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT02711553
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
NCT05506943
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
AstraZeneca
NCT05771480
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Fujifilm Pharmaceuticals U.S.A.
NCT03440450
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
XmAb20717 in Advanced Biliary Tract Cancers
Abramson Cancer Center at Penn Medicine
NCT05297903
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
NCT05220046
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
NCT04677504
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
NCT04338685
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT02829918
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
Massachusetts General Hospital
NCT00142480
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 14 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Biliary Tract Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Biliary Tract Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Biliary Tract Cancer page
37 registered trials, 24 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 24 Biliary Tract Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Biliary Tract Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Biliary Tract Cancer condition card totals 37 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.